|
|
 |
|
Viewing report
|
|
|
|
Dainippon Sumitomo: Pipeline, Products, Performance, Potential
Espicom Business Intelligence Ltd, Jan 2010, Pages: 84
Dainippon Sumitomo Pharma (DSP) is a research-based pharmaceutical company, headquartered in Osaka, which has resulted from the merger of Dainippon Pharmaceutical (which acts as the surviving company) and Sumitomo Pharmaceutical (a division of Sumitomo Chemical).
The merger was finalised and operations began on 1st October 2005, with the new company becoming the fifth largest pharmaceutical company in Japan. DSP is listed as a consolidated subsidiary of Sumitomo Chemical, which owns 50.1 per cent of the outstanding shares.
Since the merger, DSP is active in a range of therapeutic areas, principally Cardiovascular; Oncology/ Infection; Gastrointestinal; Central Nervous System (CNS); Inflammation/Allergy; and Diabetes. In the future, DSP intends to focus its product base on CNS diseases and the treatment of diabetes and associated complications.
This pharmaceutical company intelligence report provides a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.
|
|
|
|
